Skip to main content
. 2016 Mar 15;8(3):248–257. doi: 10.4251/wjgo.v8.i3.248

Table 2.

Completed adjuvant phase III trials

Ref. Treatment group Median OS (mo) 3-yr- survival 5-yr- survival
CONKO-001[38,39] Gem 22.8 37% 21%
Observation 20.2 20% 9%
ESPAC-3[40] Gem 23.6
5-FU/folinsäure 23.0
JASPAC-01[43] S1 2 yr 70%
Gem 2 yr 53%
RTOG 97-04 RCT + Gem 20.5 31% 24%
(pancreatic head)[57] RCT + 5-FU/FS 16.9 22% 11%
CONKO-005[45] Gem + Erlotinib 24.6 36% 28%
Gem 26.5 33% 19%

5-FU: 5-flourouracil; OS: Overall survival.